ReviewJournal, genetic engineering & biotechnology2025
Global research trends and therapeutic potential of fibrinolytic enzymes.
Review in Journal, genetic engineering & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibrinolytic enzymes are proteolytic enzymes that degrade fibrin clots. They play a significant role in managing thrombosis as they are crucial for the lysis of the clot. Despite the importance and extensive research on fibrinolytic enzymes, many have not been translated into therapeutics due to challenges such as immunogenicity, bleeding risks, and short half-life. Consequently, in this review, a comprehensive assessment was conducted to identify trends and gaps in fibrinolytic enzyme research, analyzing data spanning eight decades alongside important biotechnological discoveries, such as recombinant DNA technology and tissue plasminogen activators, to gain an in-depth understanding of this evolving research area. The field's multidisciplinary nature encompasses medicine, biochemistry, genetics, molecular biology, and other related disciplines, thus highlighting its industrial potential. An international collaborative network involving 35 countries was identified, highlighting the need to diversify the collaborations to advance research on fibrinolytic enzymes. At the institutional level, South Korea leads in publications, whereas research in India and Japan is more decentralized. Keyword co-occurrence analysis identified thematic clusters and journals such as Thrombosis Research and the Journal of Microbiology and Biotechnology as the prominent publishers. Patent analysis points to Cordis Corporation and Bristol-Myers Squibb as key players. This comprehensive analysis provides insights into past and current trends, highlights gaps in fibrinolytic enzyme research, and sets the stage for future advancements in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.